Aiding the “Powerhouse of the Cell”: Investigating ATP Supplementation as a Potential Therapeutic Strategy in MELAS-Associated Cardiogenic Shock

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a rare and progressive mitochondrial disorder most caused by the m.3243A>G point mutation. The disease affects multiple organ systems, including the central nervous system, muscular system, and cardiovascular system, and is associated with significant morbidity and mortality across a wide age range. Here, we present the case of a 44-year-old male with genetically confirmed MELAS who developed cardiogenic shock, multiorgan failure, and metabolic decompensation. Despite aggressive standard mitochondrial support therapy (MST), his clinical condition continued to deteriorate, ultimately resulting in death. This manuscript explores the underlying mechanisms of mitochondrial dysfunction in MELAS, with a focus on its cardiovascular complications, particularly cardiogenic shock. We further review the limitations of existing treatment options and examine the potential therapeutic role of emerging interventions such as adenosine triphosphate (ATP) supplementation, EPI-743 (vatiquinone), and intravenous nicotinamide. Our goal is to highlight the urgent need for novel and more effective interventions in this vulnerable patient population.